Ask AI
BTKi Therapy in Lymphoma

CE / CME

The APP’s Guide to Patient-Centered Management of BTK Inhibitor Therapy in Lymphoma

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: September 29, 2025

Expiration: March 28, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

All of the following are important patient comorbidities to consider when recommending specific BTK inhibitors EXCEPT:

2.

A patient is newly diagnosed with MCL. The presence of which of the following biomarkers would make this patient a possible candidate for zanubrutinib + obinutuzumab + venetoclax?

3.

Please rate your confidence on educating patients with B-cell lymphomas on the pros and cons of different BTKi treatment options to improve shared decision-making and patient adherence to their treatment plan.